comparemela.com

Page 2 - System Atrophy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alterity Therapeutics to Present New Data at the Upcoming

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to.

United statesSan franciscoDanielo claassenRemy bernardaHannah howlettDaniel claassenMargaret bradburyDavid stamlerEuropean commissionVanderbilt universityNational institute of healthParkinson foundationAmerican academy of neurologyAlterity therapeuticsInternational conferenceVanderbilt university medical center

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201.

United statesSan franciscoDavid stamlerMargaret bradburyDanielo claassenDaniel claassenRemy bernardaHannah howlettParkinson foundationEuropean commissionNonclinical developmentSecurities exchangeSystem atrophy national institute of neurological disordersVanderbilt university medical centerInternational conferenceAlterity therapeutics

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference –

United statesSan franciscoRemy bernardaHannah howlettDanielo claassenDavid stamlerMargaret bradburyDaniel claassenAlterity therapeuticsNonclinical developmentAmerican academy of neurologyVanderbilt universityNational institute of healthInternational conferenceParkinson foundationVanderbilt university medical center

Alterity Therapeutics Phase 2 Data Monitoring Committee

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06,.

San franciscoUnited statesDavid stamlerRemy bernardaHannah howlettEuropean commissionAlterity therapeuticsDrug administrationData monitoring committeeLine data expectedChief executive officerMultiple system atrophySystem atrophyMedia contactsSecurities actAustralian stock exchange ath ax

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 Alterity Therapeutics , a.

United statesSan franciscoHannah howlettRemy bernardaDavid stamlerDrug administrationData monitoring committeeSecurities exchangeSystem atrophy national institute of neurological disordersAlterity therapeuticsEuropean commissionLine data expectedChief executive officerMultiple system atrophySystem atrophyNational institute

vimarsana © 2020. All Rights Reserved.